Genzyme And Bayer Schering Pharma AG, Germany Announce Start Of Phase 3 Program With Alemtuzumab For Treatment Of Multiple Sclerosis

Genzyme Corporation (Nasdaq: GENZ) and Bayer Schering Pharma AG, Germany announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS). [click link for full article]

More: continued here

Filed under: Multiple Sclerosis on September 28th, 2007